HDM Specific Immune Globulin
Subject to the success of FDA approved human clinical trials, Quotient’s first planned product offering is to treat house dust mite allergy (“HDM”). This allergy affects 5% of the global population severely. In the United States, 1.5 to 2.0 million people are extremely impaired with this allergy, and a similar number suffer from allergic asthma with both groups not sufficiently treated by available therapies. More than $5 billion annually is being spent on the severe-disease portion of this market in the U.S. alone.
Existing allergy immunotherapy often involves multiple allergen injections for as long as 3 to 5 years, which generally have extremely poor adherence. Quotient is developing what it believes is a breakthrough immunotherapeutic approach to allergy – one with the potential to completely “turn-off” the patient’s allergic response rather than only partially reducing or masking its symptoms. The Quotient approach could provide the patient with near instantaneous results that last for approximately 30 days, after which re-dosing would be required.
Subject to the success of FDA approved human clinical trials, Quotient’s first planned product offering is to treat house dust mite allergy (“HDM”). This allergy affects 5% of the global population severely. In the United States, 1.5 to 2.0 million people are extremely impaired with this allergy, and a similar number suffer from allergic asthma with both groups not sufficiently treated by available therapies. More than $5 billion annually is being spent on the severe-disease portion of this market in the U.S. alone.
Existing allergy immunotherapy often involves multiple allergen injections for as long as 3 to 5 years, which generally have extremely poor adherence. Quotient is developing what it believes is a breakthrough immunotherapeutic approach to allergy – one with the potential to completely “turn-off” the patient’s allergic response rather than only partially reducing or masking its symptoms. The Quotient approach could provide the patient with near instantaneous results that last for approximately 30 days, after which re-dosing would be required.
Allergic Asthma
Furthermore, since HDM allergen is known to cause allergic asthma and the HDM product is expected to block the allergic response to HDM allergy (Subject to the success of FDA approved human clinical trials), Quotient believes its HDM IgG product may also prevent allergic asthma and expects off-label use may occur after regulatory approval of the HDM product. The antibody “cocktail” for the HDM product also contains the antibacterial antibody and anti-inflammatory antibody. Asthma is known as an inflammatory disease, and the allergic reaction caused by dust mite feces can lead to toxin-induced inflammation. An effective allergic asthma product could be a successful stand-alone product for Quotient while requiring a separate set of clinical trials. Quotient believes its products can re-invent these markets by “blocking” or eliminating allergy and asthmatic symptoms.
Furthermore, since HDM allergen is known to cause allergic asthma and the HDM product is expected to block the allergic response to HDM allergy (Subject to the success of FDA approved human clinical trials), Quotient believes its HDM IgG product may also prevent allergic asthma and expects off-label use may occur after regulatory approval of the HDM product. The antibody “cocktail” for the HDM product also contains the antibacterial antibody and anti-inflammatory antibody. Asthma is known as an inflammatory disease, and the allergic reaction caused by dust mite feces can lead to toxin-induced inflammation. An effective allergic asthma product could be a successful stand-alone product for Quotient while requiring a separate set of clinical trials. Quotient believes its products can re-invent these markets by “blocking” or eliminating allergy and asthmatic symptoms.